Commercial clarity for critical decisions.
Independent advisory on pricing architecture, portfolio economics, capital allocation, and acquisition assumptions. We test whether the financial case behind a commercial strategy actually holds under rigorous scrutiny.
Pricing & Margin Architecture
15–20% Margin Realization
70 Gracechurch St, London EC3V
Independent & Conflict-Free
London Practice
70 Gracechurch St, London EC3V
Commercial advice rooted in financial discipline.
Commercial questions arrive wrapped in strategy language that obscures the actual choice. P&L complexity masks where value is leaking. Pricing architecture is rarely revisited. Growth looks profitable on paper while silently draining liquidity.
Financial Discipline Over Narrative
P&L complexity frequently masks where value is leaking. We strip away strategic jargon and analyze unit economics, realized pricing, and cash flow reality.
Project-Based & Decision-Specific
We do not sell open-ended retainer bloat. Our engagements are defined by a specific boardroom decision and conclude when that decision is executed.
Uncompromising Downside Modeling
We stress-test expansion timelines, customer retention decay curves, and capital vulnerability before capital commitments become irreversible.
The recurring commercial distortions.
These are the systemic vulnerabilities we see repeatedly across mid-market and enterprise boards. We surface what standard financial reporting hides.
Pricing Disconnect from True Market Value
Most companies price relative to cost, not market value. Hidden discount structures reward negotiation over value. The gap between list price and realized price consumes 15–20% of margin on a business earning 15 points—and most companies never see it because they don't audit realized price by customer or transaction.
Invisible Contribution by Product & Channel
Standard P&L reporting obscures where profit actually originates. Volume growth often hides contribution collapse. A business might be growing top-line revenues 10% while unit contribution deteriorates rapidly, distorting capital allocation decisions.
Expansion Economics Built on Untested Facts
Revenue ramps, cost structures, and adoption curves are frequently built on optimistic base cases. Cash burn disconnects from scaling. Bad expansion decisions can consume years of accumulated balance sheet profit in months.
Fixed Cost Traps Dictated by History
Capacity decisions made years ago determine vulnerability to macro pressure. Most companies never model the financial impact if revenue contracts 20%. A business with 35% fixed overhead cannot survive sustained downturns without pre-emptive restructuring.
M&A Synergies Assumed Rather Than Proven
Deal teams are incentivized to close. Strategic synergies are assumed rather than proven, and integration drag is underestimated. The difference between value creation and destruction is decided at the due diligence stage, not post-merger.
Capital Allocation Driven by Momentum
Competing investments are rarely evaluated under a unified economic standard. A business allocating capital at an 8% return when its weighted average cost of capital is 10% silently destroys shareholder value every operating year.
Where these vulnerabilities concentrate.
Industry-specific patterns where unit contribution gets misread, capital gets trapped, and top-line expansion diverges from cash generation.
Software & High-Growth SaaS
Cohort Margins & Retention DecayUnit economics look pristine until disaggregated by acquisition vintage. A 10-year-old cohort may subsidize newer cohorts that are value-destructive. Churn dynamics are embedded in valuation multiples but rarely audited in strategic pricing reviews.
Manufacturing & Precision Engineering
Operating Leverage & Capacity ExposureHistorical capex decisions dictate acute vulnerability to revenue contractions. If 40% of the cost structure is fixed, a 20% decline in volume collapses operating margin. Investment models assume peak utilization; downturns leave capacity stranded.
Financial Services & Capital Markets
Customer Mix & Regulatory Capital DragRealized profitability is driven far more by customer tiering than operational efficiency. Regulatory capital reserves constrain balance sheet velocity. Misallocating focus to low-margin volume rapidly destroys economic return on capital.
Healthcare & Life Sciences
R&D Concentration & Portfolio PaybackPortfolio economics are heavily skewed: a handful of late-stage assets determine firm-wide returns. R&D capital sits unproductively in programs that will never clear commercial reimbursement thresholds without aggressive portfolio culling.
Private Equity & Sponsor-Backed Assets
Hold Period Realization & Multiple ExpansionValue creation plans embed aggressive assumptions regarding organic pricing power and multiple expansion. We help sponsors and executive teams stress-test commercial theses before commitments form the basis of an M&A transaction.
Three pillars of our scrutiny.
We stress-test commercial logic, downside exposure, and capital return. This is how we think.
Separate Critical Drivers from Decorative Assumptions
Every major strategic recommendation depends on two or three assumptions doing 80% of the financial heavy lifting. We isolate those critical levers, audit them against empirical transaction data, and model what occurs if the core thesis deviates by 20%, 40%, or 60%.
Force Rigorous Downside Modeling into the Room
Downside modeling is not pessimism—it is the disciplined interrogation of systemic fragility. We evaluate slower market ramp rates, aggressive competitor counter-pricing, and capital lockups to determine whether the strategic call remains robust if base cases fail.
Structure Risk-Mitigated, Staged Commercial Options
Once risk sensitivities and downside boundaries are transparent, false binary choices dissolve. We formulate staged investment tranches, milestone-contingent capital releases, and variable pricing structures that preserve upside while safeguarding downside liquidity.